Vijendra Singh

This week's NEJM on MGUS: Recommends 24h urine protein electrophoresis for all M protein patients. But is any urine protein testing needed in low-risk MGUS with normal kidney & albumin, let alone 24h? Thoughts?@VincentRK@amyloid_planet. #MGUS #Hematology #NEJM

@nikhil_vojjala @Amyloid_Planet @GK_SJMO @KarmanosHemeOnc @deevyaparekh Congratulations Nikhil

Happy to share, I have received YIP award, SOHO 2025 for old yet unanswered question: Len vs Mel oncogenic potential ! Grateful to my mentors ⁦@vijsinghmd⁩ ⁦@Amyloid_Planet⁩ ⁦@GK_SJMO⁩ ⁦⁦@KarmanosHemeOnc⁩ and ⁦@deevyaparekh⁩ for collaboration!

⚖️ The 20% cutoff holds strong for venetoclax-based therapies, thanks to VIALE-A’s success. VERONA’s negative result questions the 10-20% range for now. More granular data needed from VERONA ! 4/5

💊 VIALE-A (AML, >20% blasts) showed venetoclax + azacitidine as a game-changer—clear survival benefits! VERONA (10-20% blasts, MDS/AML) didn’t hit the mark. 3/5

🧬 WHO vs. ICC: The 20% vs. 10% blast cutoff debate in MDS/AML continues! VIALE-A and VERONA trials tip the scales toward WHO’s 20%. Let’s unpack this!

Check out our Poster #63 #ASCO discussing the largest real-world study on t-MN incidence with RAI (Pluvicto and Lutathera) in n=2370. Overall risk is 1.6% at a median follow-up of 27.3 months: 1.9% with Lutathera, 1.2% with Pluvicto.@nikhil_vojjala @vijsinghmd

Hot off the press ! Outcomes of respiratory syncytial virus infection among hospitalized adults with hematological malignancies. Forever grateful to my mentors ! @vijsinghmd @GK_SJMO tandfonline.com/doi/full/10.10…

Mark your calendars! The MSHO Hematology Jeopardy Quiz kicks off Fri, April 12, 2025—fun, learning, & heme vibes await! #MSHOJeopardy msho.org/aws/MSHO/asset…

Excited to share that our abstract accepted for ASCO residents forum ! Cannot wait for final ASCO abstract results ! ⁦@ASCO⁩ Thanks to my mentors for the opportunity! ⁦@vijsinghmd⁩ ⁦@ibrahimazaronc⁩ ⁦@KarmanosHemeOnc⁩ ⁦@THO_WSU_IM⁩

Happy to share that our article on “Acquired haemophilia - Readmissions and outcomes” is accepted for publication in VTH- ASH journal. Thanks to my mentors for the support ⁦@vijsinghmd⁩ @aditi Sharma ⁦@KarmanosHemeOnc⁩ ⁦@karmanoscancer⁩ ⁦@THO_WSU_IM⁩

It’s a proud moment for us! ASH awards 2024 Mentor award to Dr.Schiffer. #ASH24 @ASH_hematology @waynestate @karmanoscancer

Please check out our poster at 3717 #ASH 24.Grateful to present on “Mortality characteristics of RSV Hospitalisation among patients with Haematological malignancies-Paving way for Universal RSV Vaccination”Thanks to my mentors! ⁦@vijsinghmd⁩ ⁦@KarmanosHemeOnc⁩⁦

Please stop by our poster at 3717 #ASH24 “Mortality characteristics of RSV Hospitalisations” ✔️Statistically significant higher mortality rates in hematological malignancies in general and NHL subgroup under 60 years of age ! ⁦@vijsinghmd⁩ ⁦@KarmanosHemeOnc⁩ ⁦

@AaronGoodman33 unfortunate that medical students need to learn the things which 99.9% will never see in their life time. HTLV-1 should not be part of USMLE. If something look fancy , doesn’t mean medical students should know about it. It’s fellowship level stuff.

🚨Melphalan Dose in FluMel RIC condition regimen for AML and MDS: Mel100 vs Mel140 associated with lower risk of GI toxicity and cGVHD with no impact on relapse,NRM and OS. ⁦@ASTCT_Journal⁩ ⁦@MoffittNews⁩ ⁦@KFSHDammam⁩ astctjournal.org/article/S2666-…

Dr. Jay Yang @karmanoscancer starting off the Annual Lymphoma Symposium with a great presentation on CLL ! Continuos vs time limited therapy for frontline CLL

Congratulations Dr. Charles Schiffer, retired Karmanos hematologist and medical oncologist, for receiving one of two Mentor Awards from the American Society of Hematology! #YourBestChance To read more about this accomplishment, click below. mclarenhealthcare.org/3zRYbjt

A very well deserved award for Dr. Schiffer ! karmanos.org/karmanos/news/…

Glad to share that our real world analysis on Isovolumic Hemodilution RBC exchange in patients with SCD has been accepted for presentation at AABB 2024 annual meeting. Grateful to mentors for their constant support ! @vijsinghmd @ Asif Alavi @AABB @ASH_hematology